Clinical Trial Update: Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal

View source ↗

Summary

A real-world analysis from Portugal examining usage patterns and dosing of CDK4/6 inhibitors for breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)
• KISQALI (ribociclib)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Status: COMPLETED